| アブストラクト | Janus kinase inhibitors (JAKi) are drugs that block tyrosine kinases responsible for transducing cytokine signals. The first JAKi was approved by the US Food and Drug Administration (FDA) in 2011 to treat rheumatoid arthritis in adults. A pediatric indication was not approved until 8 years later, for acute graft-versus-host disease. Since then, topical and oral formulations have gained FDA approval for pediatric patients with dermatologic diseases. While increasing evidence supports the safety of these medications in adults, data are limited in children. We sought to determine whether JAKi adverse events (AEs) as reported in clinical trials and via postapproval pharmacovigilance services are comparable in adult and pediatric patients. Pharmacovigilance data were extracted from the FDA's Adverse Event Reporting System and the Canada Vigilance Adverse Reaction Online Database for baricitinib, upadacitinib, abrocitinib, ruxolitinib, and tofacitinib. The pooled data were analyzed to detect the most common AEs for specific JAKi and for the drug class. We assessed 399,649 AEs from 133,216 adults and 2883 AEs from 955 patients under 18 years old and identified slightly different AE profiles for the two age groups. Both populations had increased risk for infections and gastrointestinal AEs. However, pediatric patients reported a higher proportion of blood and lymphatic disorders, while reports of nervous system and musculoskeletal/connective tissue disorders were more common in adults. The spectrum of AEs extracted from pharmacovigilance reports was similar to clinical trials. The JAKi AE profiles we observed may prove helpful in counseling patients and their parents before starting therapy and for monitoring once patients are on therapy. |
|---|
| ジャーナル名 | Pediatric dermatology |
|---|
| Pubmed追加日 | 2024/9/5 |
|---|
| 投稿者 | Talasila, Sahithi; Lee, Emily; Teichner, Eric M; Siegfried, Elaine C; Jackson Cullison, Stephanie R |
|---|
| 組織名 | Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia,;Pennsylvania, USA.;Saint Louis University and SSM Cardinal Glennon Children's Hospital, St. Louis,;Missouri, USA.;Department of Dermatology and Cutaneous Biology, Thomas Jefferson University,;Philadelphia, Pennsylvania, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39235110/ |
|---|
